Breadcrumb

[A18-78] Tildrakizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2018-11-13 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 83 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form

Report documents

Report documents

PublishedDocumentSizeType 
2019-02-15 Extract of dossier assessment 83 kBPDFdownload file
2019-02-15 Dossier assessment (German version) 338 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Tildrakizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V [PDF, 83 kB]

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Tildrakizumab (EU: Ilumetri, U.S.: Ilumya) for the treatment of psoriasis

Federal Joint Committee (G-BA)

2019-05-02 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close